Review of Changes in Topical Drug Product Classification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Review of Changes in Topical Drug Product Classification
This article summarizes the classification systems for topical liquid and semisolid dosage forms used for dermatological application and notes some differences between FDA and USP classification.


Pharmaceutical Technology
Volume 32, Issue 10, pp. 66-74


Dosage forms to deliver pharmaceutical actives to the skin (definitions provided in Reference 5. Bolded entries are terms being phased out of USP titles)
If the dosage form is a liquid or semisolid, and not listed in Tables, then the next question in the decision tree is, Is it a liquid or a semisolid? (4). To help answer this question, Buhse et al. and CDER Data Sandards Manual define liquid as being pourable; it flows and conforms to its container at room temperature, and displays Newtonian or pseudoplastic flow behavior. A semisolid is defined as not being pourable; it does not flow or conform to its container at room temperature. It does not flow at low-shear stress and generally exhibits plastic flow behavior (4, 6). Thus to distinguish between a liquid and a semisolid, a rudimentary understanding of plastic and pseudoplastic flow behavior and Newtonian liquids is required. Because these references do not define these terms, it appears in keeping with FDA's interpretation to use descriptive definitions.

Newtonian fluids such as water and solutions containing only low molecular-weight material are characterized by viscosity that is independent of the rate of stirring. Thus, a plot of shear rate versus shear stress is linear and passes through the origin. Pseudoplastic flow behavior is characterized by viscosity decreasing with the rate of shear (i.e., shear thinning). Plastic flow behavior is characterized by a material behaving as a solid until a threshold stress is reached beyond which the material flows. The slope of the rheogram can be extrapolated to determine the yield value. Because a threshold stress is required before flow, the plot of shear rate versus shear stress can not pass through the origin for a material having plastic flow. Based on the data presented by Buhse et al., the plot of shear rate versus shear stress for both pseudoplastic liquids and plastic semisolids are characterized by a yield value (D/cm2 ) and a curved response to changes in shear rate (4). In a presentation, Buhse suggested that semisolids have yield values ≥ 200 D/cm2 , and liquids capable of conforming to the container have yield values <200 D/cm2 (12).

Solutions, suspensions, and lotions

Once it is decided that a liquid is being applied to the skin surface, the next question in the decision tree is, Is the liquid clear and homogeneous, a solid dispersed in a liquid, or an emulsion? (4). If the liquid is clear and homogeneous, then the dosage form is classified as a solution. A solution is defined as "a clear, homogeneous liquid dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents." If the product is a solid dispersed in a liquid, then the dosage form is classified as a suspension. Suspension is defined as "a liquid dosage form that contains solid particles dispersed in a liquid vehicle." If the liquid is an emulsion, then the dosage form is classified as a lotion.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here